Fig. 2

S100A7 regulates cPLA2-mediated PGE2 generation in breast cancer. Immunoblot analysis of S100A7 and cPLA2 proteins in (A). MDA-MB-231 vector (231 V) and S100A7 overexpression (S7OE-231) cells (B). MDA-MB-468 vector (468 V) and S100A7 knockdown (S7KD-468) cells (C). Immunoblot analysis of cPLA2 in S7OE-231 cells treated with vehicle control (DMSO) or RAGE inhibitor (FPS-ZM1) for 24 h. The bar diagram showing the levels of PGE2 (pg/mL) in conditioned medium (CM) harvested from (D). 231 V and S7OE-231 cells, and (E). 468 V and S7KD-468 either treated with vehicle control (VC) or AACOCF3 (AF3). Analysis of PGE2 (pg/mL) in CM of (F) S100A7-overexpressing and (G). MDA-MB-468 cells transiently transfected with scramble control (Scr) or PLA2G4A-siRNA. Estimation of (H). S100A7 (ng/mL) and (I). PGE2 (pg/mL) in blood plasma samples of normal subjects (n = 18) and breast cancer patients (n = 62) (J). Correlation between blood plasma level of S100A7 (ng/ml) and PGE2 (pg/ml) in breast cancer patients (n = 70). ns: non-significant, *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. t test and one way ANOVA was used for calculating statistical significance